Market Place
Sourcing Support
Halia`s takes NLRP3 inhibitor into final stage of Phase 2 trial
11 Dec 2024 //
PRESS RELEASE
Halia Therapeutics Advances HT-6184 to Stage 2 Ph 2 in Low-Risk MDS
10 Dec 2024 //
PR NEWSWIRE
Halia Therapeutic Presents HT-6184 Weight Loss Data at Obesity Week
31 Oct 2024 //
PR NEWSWIRE
Halia Therapeutics to Participate in Panel at BIO Investor Forum 2024
14 Oct 2024 //
PR NEWSWIRE
Halia Therapeutics Doses First Volunteer With HT-4253 For Alzheimer`s
07 Oct 2024 //
PR NEWSWIRE
Halia To Present HT-6184 Phase II Data At Inflammasome Summit
10 Sep 2024 //
PR NEWSWIRE
Halia Therapeutics CEO To Present At Global Longevity Federation
06 Aug 2024 //
PR NEWSWIRE
Halia And Biolexis Identify Candidate For NLRP3-Driven Neuroinflammation
31 Jul 2024 //
PR NEWSWIRE
Halia At BIO And European Hematology Congress Events
30 May 2024 //
PR NEWSWIRE
Halia To Unveil New Alzheimer`s LRRK2 Program At Discovery Europe 2024
14 May 2024 //
PR NEWSWIRE
Halia Therapeutics to Present at Asia BIO 2024
17 Apr 2024 //
PR NEWSWIRE
Halia Therapeutics Announces Collaboration with Canary Speech
06 Feb 2024 //
PR NEWSWIRE
Halia to Present at the 13th World Gastroenterology, IBD & Hepatology Conference
15 Dec 2023 //
PR NEWSWIRE
Halia Therapeutics Dosed its First Patient in Phase 2a Clinical Trial of HT-6184
13 Dec 2023 //
PR NEWSWIRE
Halia Therapeutics to Present Preclinical Data at the 65th ASH Annual Meeting
27 Nov 2023 //
PR NEWSWIRE
Halia Therapeutics to Present at the 5th Inflammasome Therapeutics Summit
20 Nov 2023 //
PR NEWSWIRE
Halia Appoints Former Amgen Scientists, Lisa Shamon as Vice President
16 Nov 2023 //
PR NEWSWIRE
Halia Continued Support to Utah`s Industry Community Recognized by First Place
31 Oct 2023 //
PR NEWSWIRE
Halia Therapeutics to Present at the 17th Annual Pain Therapeutics Summit
18 Oct 2023 //
PR NEWSWIRE
Halia Therapeutics to Present at the 17th Annual PAINWeek Conference
31 Aug 2023 //
PR NEWSWIRE
Halia Therapeutics Opens the Doors of its New Headquarters in Lehi, Utah
16 Aug 2023 //
PR NEWSWIRE
Halia Announces Completion of Enrollment for Phase I Clinical Trial of HT-6184
07 Aug 2023 //
PR NEWSWIRE
Halia Therapeutics to Present at the 2023 BIO CEO & Investor Conference
30 Jan 2023 //
PR NEWSWIRE
Halia Appoints Former Amgen Executive, Margit M. Janát-Amsbury as CMO
19 Jan 2023 //
PR NEWSWIRE
Halia Therapeutics Presents at 4th Inflammasome Therapeutics Summit
01 Dec 2022 //
BUSINESSWIRE
Halia doses first subject in Phase I trial of chronic inflammation asset
16 Jun 2022 //
CLINICALTRIALSARENA
Halia Begins Dosing in PI Study of HT-6184
15 Jun 2022 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.